|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In September , Venaxis Inc., a Castle Rock medical device company, acquired Bioptix Diagnostics Inc. of Boulder and renamed itself Bioptix Inc. T hat acquisition quickly turned nasty with a major shareholder accusing company executives of "an inside management job," with executives firing back at the shareholder. And earlier this month after the 2016 drama, Bioptix shook up its board and said three of its board members are leaving, including the former lieutenant governor of Colorado.
BOULDER, Colo., Dec. 8, 2016 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), announced that following the approval from shareholders at the 2016 Annual Meeting of Shareholders of the proposal to change ...
Categories: Yahoo Finance Get free summary analysis Venaxis, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Venaxis, Inc. – Vermillion, Inc., Chembio Diagnostics, Inc., OraSure Technologies, Inc., Alere Inc., Echo Therapeutics, Inc., American Bio Medica Corporation and Myriad Genetics, Inc. (VRML-US, CEMI-US, OSUR-US, ALR-US, ECTE-US, ... Read more (Read more...)